Alset Inc. (formerly Alset EHome International Inc.) — Form 8-K Summary
Reporting date: November 4, 2021; filed November 5, 2021. This Form 8-K reports events under Regulation FD and other events. It does not provide a quarterly or annual financial reporting period or comparative operating results.
Business Context
AEI furnished a press release regarding AMRE’s acquisition of three hospitals located in Fort Worth, Texas; Plano, Texas; and Pittsburgh, Pennsylvania. The filing text does not provide the acquisition price, hospital operating metrics, financing terms, closing conditions, or expected financial contribution.
AEI’s majority-owned subsidiary, Alset International Limited (AIL), and related entities provided financing to American Medical REIT Inc. (AMRE). AEI owns approximately 41.3% of American Pacific Bancorp, Inc. (APB), one of the lenders.
Financing and Key Financial Terms
| Instrument | Principal | Interest | Maturity and conversion terms |
|---|---|---|---|
| AIL convertible note to AMRE | $8.35 million | 8.00% annually, payable quarterly beginning January 29, 2022 | Due on demand; otherwise due 25 months after October 29, 2021. Convertible at AIL’s option into AMRE common stock at $10.00 per share. |
| APB convertible note to AMRE | $13.940 million | 8.00% annually, payable quarterly beginning January 29, 2022 | Due on demand; otherwise due 25 months after October 29, 2021. Convertible at APB’s option into AMRE common stock at $10.00 per share. |
| LiquidValue note to AMRE | $200,000 | 8.00% annually, payable annually in arrears | Matures October 29, 2024; prepayable without penalty. |
The two convertible notes total $22.29 million in principal. AMRE may prepay or repay either convertible note without premium or penalty upon 30 days’ written notice. The notes are due on demand, creating potential near-term liquidity exposure for AMRE.
LiquidValue, a wholly owned subsidiary of AIL, also received a warrant. The initial exercise price is $5.00 per AMRE share, and the warrant may be exercised from October 29, 2021 through the fourth anniversary of that date. Based on the stated formula, the initial warrant amount corresponds to 40,000 shares, subject to the definitive warrant terms.
Material Changes, Outlook, and Risks
- The filing discloses new lending and potential equity-conversion exposure to AMRE, but provides no revenue, earnings, cash-flow, margin, debt-ratio, or liquidity metrics for AEI.
- Interest income from the notes is expected to accrue at 8.00%, but the filing does not quantify the expected impact on AEI’s consolidated results.
- Conversion of the notes could result in AMRE equity ownership rather than cash repayment and may create dilution for AMRE shareholders.
- The filing does not provide management guidance or a quantified outlook.
- Material risks include AMRE’s ability to repay principal and interest, the enforceability and timing of demand repayment, the value and liquidity of AMRE common stock, and the results of the hospital acquisition.
- The filing states that the press release is furnished, not filed, and is not incorporated by reference except as expressly specified.
Important Facts for Investors to Verify
- Obtain and review the full AMRE hospital acquisition announcement, including purchase price, financing, assets acquired, operating results, and closing status.
- Review the executed AIL, APB, and LiquidValue notes, subscription agreements, and warrant for repayment priority, default provisions, security, conversion mechanics, and related-party terms.
- Confirm the accounting treatment and carrying values of the notes, accrued interest, warrant, and AEI’s investment in APB.
- Assess AMRE’s liquidity and ability to satisfy demand repayment obligations or make quarterly interest payments.
- Confirm the definitive warrant share count and potential dilution based on the $5.00 exercise price.